FDA to weigh lifting restrictions on some MAHA-favored peptides

The Food and Drug Administration (FDA) is taking the first steps toward potentially easing access to certain peptide injections that are currently restricted due to safety concerns. The agency on Wednesday said it is convening a meeting of an outside advisory panel in July to discuss whether to allow compounding pharmacies to manufacture peptides for ulcerative colitis, wound healing, obesity and
Source
The Hill
Opens original article in a new tab


